Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07226726

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Congenital Myasthenic Syndrome Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Myasthenic Syndromes, Congenital Nervous System Diseases Neuromuscular Diseases Neuromuscular Junction Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Medical Surgical Associates Center, St John's, Antigua and Barbuda

Loading trial locations.

About this study

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
  • Patients must be able to provide informed consent, or have a guardian who does.
  • Patient must be able to travel to the site of treatment.

Exclusion criteria

  • Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.

Treatment and study plan

AlloEx exosomes

Biological

This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Primary outcomes

  1. Oxygen Saturation

    Time frame: From enrollment to 6 months after treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Chadwick Prodromos

CONTACT

[email protected]

18476996810

Sponsors and collaborators

Lead sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Other

Registry information

Official study title

Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Nov 10, 2025
Registry last updated
Nov 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.